Navigation Links
VIVUS Announces New Qsymia Offer
Date:3/5/2013

us.com/">www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our limited commercial experience with Qsymia in the U.S.; the timing of initiation and completion of the clinical studies required as part of the approval of Qsymia by the United States Food and Drug Administration, or FDA; the response from the FDA to the data that VIVUS will submit relating to post-approval clinical studies; the impact of the indicated uses and contraindications contained in the Qsymia label and the Risk Evaluation and Mitigation Strategy, or REMS, requirements; the impact of distribution of Qsymia through a certified home delivery pharmacy network; whether or not the FDA approves our amendment to the REMS for Qsymia, which, if approved, would allow dispensing through select certified retail pharmacies to increase access while meeting all requirements of the REMS; that we may be required to provide further analysis of previously submitted clinical trial data; the negative opinion of the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, for the Marketing Authorization Application, or MAA, for Qsymia; our ability to successfully commercialize or establish a marketing partnership for avanafil, which will be marketed in the U.S. under the name STENDRA™; the ability of our partners to obtain and maintain regulatory approvals to manufacture and adequately supply our products to meet demand; our history of losses and v
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom Announces Participation At The Barclays Global Healthcare Conference
2. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
3. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
4. SI-BONE, Inc. Announces Spring Society Meeting Attendance
5. Relmada Therapeutics Announces LevoCap ER Development Progress
6. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
7. Evofem Announces Strategic Alliance with WomanCare Global
8. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
9. Hill-Rom Announces Second Quarter 2013 Dividend
10. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
11. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... the Phase 3 clinical development of Revolixys™ Kit (previously ... system, today announced that it will hold a conference ... 2014, at 8:30 a.m. EDT to discuss its second ... Interested participants and investors may access the conference call ...
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. ... is participating in two healthcare conferences during the third ... the Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate ... Conference.  The details on each event are below: ... August 11, 2014 in Boston , ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... Five Posters Scheduled for the 2008 Annual Meeting ... Vision and Ophthalmology (ARVO), IRVINE, Calif., Feb. ... announced today the acceptance of an abstract,describing the ... 0.09% therapy in combination with Lucentis(R) (ranibizumab,injection) in ...
... Flawed policies and,bad decisions at the FDA have contributed ... now take an average of one billion dollars and,require ... prevented the,availability of many promising treatment options, resulting in ... cost of medical,treatment in the United States., It,s ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R) 2ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R) 3ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R) 4ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R) 5Cancer Cure Coalition Proposes Major Changes at the FDA 2Cancer Cure Coalition Proposes Major Changes at the FDA 3
(Date:7/29/2014)... SC (PRWEB) July 29, 2014 During his ... L. Bruce, DMD & Associates, has had a steady stream ... about dentistry. These students have now gone on to dental ... practices, proving that the shadowing program helps college students find ... Dr. Bruce has given them the chance to see a ...
(Date:7/29/2014)... of Medicine researchers have made an important advancement ... potentially deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). ... seen a steady rise in the incidence of ... making the need for a vaccine critical. Successful ... to prevent disease, and the VCU team has ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Bret ... LLP ’s Boise office, has been appointed to the ... Greater Idaho. , Busacker is an experienced business attorney ... matters. He advises clients on a wide spectrum of ... plan administration, compliance, and governance concerns. His clients include ...
(Date:7/29/2014)... cancer is to surgically remove the tumor. The Achilles ... may fail to extract the entire tumor, leading to ... at the University of Pennsylvania have established a new ... the patient, increasing the likelihood of a positive outcome. ... in cancerous tissues much more so than normal tissues. ...
(Date:7/29/2014)... Helping people recover from the debilitating effects ... requires deep knowledge of neurophysiology as well as effective ... outcomes has been the primary focus of research by ... joined the NJIT faculty more than a decade ago. ... funding from sources such as the National Institutes of ...
Breaking Medicine News(10 mins):Health News:Arthur Bruce Dental Helps College Students 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Continuing the Quest for Better Stroke Therapies 2Health News:Continuing the Quest for Better Stroke Therapies 3Health News:Continuing the Quest for Better Stroke Therapies 4
... ... accident, persuades jury that defendants were 100% responsible for client’s accident. , ... New York (Lexis Nexis) November 30, 2009 -- ... who was injured at a New York City construction site in 2004., , ,The case, ...
... , CLEVELAND, Ohio, November 30 ... simulation systems, in collaboration,with GORE Medical Products will be ... at the upcoming ICCA Meeting in Frankfurt,Germany. , ... the world,s first medical,simulator to enable clinicians to create ...
... CHICAGO Elastography is an effective, convenient technique ... cancerous breast lesions from benign results, according to ... meeting of the Radiological Society of North America ... often use ultrasound to obtain additional information. However, ...
... ... Dentistry (AGD) announces that Aria Irvani, DDS, of Orange county CA, received the Mastership ... dental education.,To accomplish this, Dr. Irvani completed 1,100 hours of approved continuing dental education ... techniques. , ...
... For well-being, a $1,300 round of treatment equals a ... (HealthDay News) -- Psychological therapy may be much more ... or winning a lottery prize, suggests an English study. ... provided information about their mental well-being and found that ...
... Nov. 28 Get ready for advanced visualization to ... Siemens introduces syngo. via(1) at ... North America (RSNA) from November 29 to December 3 at McCormick Place ... syngo. via , Siemens, new imaging ...
Cached Medicine News:Health News:Raphaelson & Levine Secures $1.1 Million Verdict for Victim of New York Construction Accident 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 2Health News:Simbionix First Procedure Rehearsal Studio(TM) Training Workshop 3Health News:Elastography reduces unnecessary breast biopsies 2Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: